NCCN Guidelines Insights: Breast Cancer, Version 1.2017
William J. Gradishar(Western University), Benjamin O. Anderson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ronald Balassanian(UCSF Helen Diller Family Comprehensive Cancer Center), Sarah L. Blair(Moores Cancer Center), Harold J. Burstein(Dana-Farber Brigham Cancer Center), Amy Cyr(Jewish Hospital), Anthony Elias(University of Colorado Cancer Center), William B. Farrar(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Andres Forero(University of Alabama at Birmingham), Sharon H. Giordano(The University of Texas MD Anderson Cancer Center), Matthew P. Goetz(Fox Chase Cancer Center), Lori J. Goldstein(Fox Chase Cancer Center), Steven J. Isakoff(University of Wisconsin Carbone Cancer Center), Janice A. Lyons(Cancer Institute (WIA)), P. Kelly Marcom(Duke Medical Center), Ingrid A. Mayer(Breast Cancer Research Foundation), Beryl McCormick(Memorial Sloan Kettering Cancer Center), Meena S. Moran(Yale Cancer Center), Ruth O’Regan(University of Wisconsin Carbone Cancer Center), Sameer A. Patel(University of Wisconsin Carbone Cancer Center), Lori J. Pierce(Roswell Park Comprehensive Cancer Center), Elizabeth Reed(University of Wisconsin Carbone Cancer Center), Kilian Salerno(University of Wisconsin Carbone Cancer Center), Lee S. Schwartzberg(University of Tennessee Health Science Center), Amy M. Sitapati(Moores Cancer Center), Karen L. Smith(Sidney Kimmel Comprehensive Cancer Center), Mary Lou Smith(Research Advocacy Network), Hatem Soliman(University of Wisconsin Carbone Cancer Center), George Somlo(City of Hope), Melinda L. Telli(Stanford Cancer Institute), John H. Ward(Huntsman Cancer Institute), Dorothy A. Shead(National Comprehensive Cancer Network), Rashmi Kumar(National Comprehensive Cancer Network)
Cited by 541Open Access
Abstract
These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.
Related Papers
No related papers found
Powered by citation graph analysis